Drug intelligence / Profile preview

H7N9c vaccine

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The **H7N9c vaccine** is a candidate vaccine designed to prevent infection caused by the avian influenza A(H7N9) virus. It is a monovalent inactivated influenza vaccine (IIV) formulated specifically against the H7N9 influenza strain, and may be combined with different adjuvants to enhance immunogenicity. Clinical trials have primarily tested it with adjuvants such as AS03 or MF59, with studies indicating that non-aluminum adjuvants (e.g., MF59, AS03, ISCOMATRIX) significantly improve the immune response compared to aluminum adjuvants or non-adjuvanted formulations[1][5].

Other names: H7N9c vaccineH-7N9c vaccineH 7N9c vaccine

Targets

H7N9 HA stalk (Influenza A H7N9 hemagglutinin stalk domain)HA (Hemagglutinin)

Beyond the preview

Go deeper on H7N9c vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H7N9c vaccine.

Explore the full profile